Ana Beatriz Pizarro

Ana Beatriz Pizarro

Auto-generated profile, based on publicly available information

Ana Beatriz Pizarro

Clinical Research Center, Fundacion Valle del Lili, Cali, Colombia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Nepal Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
BSBrijesh Sathian
Brijesh Sathian
DADr. Mohammad Asim
Dr. Mohammad Asim
IBIndrajit Banerjee
Indrajit Banerjee
APAna Beatriz Pizarro
Ana Beatriz Pizarro
BRBedanta Roy
Bedanta Roy
HAHanadi Khamis Alhamad
Hanadi Khamis Alhamad
Background: The World Health Organization has reported more than 31,186,000 confirmed cases of coronavirus disease-19 (COVID-19), including 962,343 deaths, worldwide as on September 21, 2020. The current COVID-19 pandemic is affecting clinical research activities in most parts of the world. The focus on developing a vaccine for SARS-CoV-2 and the treatment of COVID-19 is, in fact, disrupting many upcoming and/or ongoing clinical trials on other diseases around the globe. On March 18, 2020, the United States Food and Drug Administration (FDA) issued an updated guideline for the conduct of clinical trials during the current health emergency situation. The potential challenges, such as social distancing and quarantines, result in study participants’ inaccessibility and trial personnel for in-person scheduled study visits and/or follow-up. Due to the sudden onset and wide-spread impact of COVID-19, its influence on the management of clinical trials and research necessitates urgent attention. Therefore, our systematic review of the literature aims to assess the impact of the COVID-19 pandemic on the conduction of clinical trials and research. The search for the relevant articles for review included the keywords "COVID-19” AND "clinical trial" in PubMed, MEDLINE, Embase, Google scholar and Google electronic databases. Key findings include: delaying subject enrollment and operational gaps in most ongoing clinical trials, which in turn has a negative impact on trial programmes and data integrity. Globally, most sites conducting clinical trials other than COVID-19 are experiencing a delay in timelines and a complete halt of operations in lieu of this pandemic, thus affecting clinical research outcomes.

1 September 2020 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
AFAlireza Farsad-Naeimi
Alireza Farsad-Naeimi
FAFoad Asjodi
Foad Asjodi
MOMahsa Omidian
Mahsa Omidian
MAMohammadreza Askari
Mohammadreza Askari
MNMehran Nouri
Mehran Nouri
EDElnaz Daneshzad
Elnaz Daneshzad

1 November 2020 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
RPRazieh Pirouzeh
Razieh Pirouzeh
NHneda Heidarzadeh-Esfahani
neda Heidarzadeh-Esfahani
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
AIAzimeh Izadi
Azimeh Izadi
SYSomaye Yosaee
Somaye Yosaee
SHShilan Heshmati
Shilan Heshmati

1 November 2020 in Food Research International
Verified
Journal Article
Closed access
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
SNSeyed Mostafa Nachvak
Seyed Mostafa Nachvak
SAShahram Agah
Shahram Agah
MSMahdi Sepidarkish
Mahdi Sepidarkish
FDFereshteh Dehghani
Fereshteh Dehghani
MJMojgan Javad
Mojgan Javad

1 September 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AAAbolfazl Akbari
Abolfazl Akbari
MSMeghdad Sedaghat
Meghdad Sedaghat
JHJavad Heshmati
Javad Heshmati
STSeidamir Pasha Tabaeian
Seidamir Pasha Tabaeian
SDSadegh Dehghani
Sadegh Dehghani
RHRasoul-akram hospital
Rasoul-akram hospital
Curcumin is a bioactive ingredient found in the Rhizomes of Curcuma longa. Curcumin is well known for its chemopreventive and anti-cancer properties. Recent findings have demonstrated several pharmacological and biological impacts of curcumin, related to the control and the management of gastrointestinal cancers. Mechanistically, curcumin exerts its biological impacts via antioxidant and anti-inflammatory effects through the interaction with various transcription factors and signaling molecules. Moreover, epigenetic modulators such as microRNAs (miRNAs) have been revealed as novel targets of curcumin. Curcumin was discovered to regulate the expression of numerous pathogenic miRNAs in gastric, colorectal, esophageal and liver cancers. The present systematic review was performed to identify miRNAs that are modulated by curcumin in gastrointestinal cancers.

31 July 2020 in Medwave
Verified
Journal Article
Closed access
Eduard BaladiaEduard Baladia
Eduard Baladia
APAna Beatriz Pizarro
Ana Beatriz Pizarro
LOLuis Ortiz-Muñoz
Luis Ortiz-Muñoz
GRGabriel Rada
Gabriel Rada
This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19. We conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission). We adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates. We screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19. We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon. CRD42020181216.